{"id":"NCT02111577","sponsor":"SOTIO a.s.","briefTitle":"Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer","officialTitle":"A Randomized, Double Blind, Multicenter, Parallel-group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men With Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05-26","primaryCompletion":"2020-01-28","completion":"2020-01-28","firstPosted":"2014-04-11","resultsPosted":"2021-04-06","lastUpdate":"2021-04-06"},"enrollment":1182,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Metastatic Castration-resistant Prostate Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"DCVAC/PCa","otherNames":["Stapuldencel"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"DCVAC/PCa with standard of care chemotherapy","type":"EXPERIMENTAL"},{"label":"Placebo with standard of care chemotherapy","type":"PLACEBO_COMPARATOR"}],"summary":"The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in patients with metastatic castration-resistant prostate cancer.","primaryOutcome":{"measure":"Overall Survival, Intention-to-treat Population","timeFrame":"From randomization to death due to any cause, up to 58 months","effectByArm":[{"arm":"DCVAC/PCa With Standard of Care Chemotherapy","deltaMin":23.9,"sd":null},{"arm":"Placebo With Standard of Care Chemotherapy","deltaMin":24.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.596"},{"comp":"OG000 vs OG001","p":"0.648"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":12},"locations":{"siteCount":177,"countries":["United States","Austria","Belarus","Belgium","Bulgaria","Croatia","Czechia","Denmark","France","Germany","Hungary","Italy","Latvia","Lithuania","Netherlands","Poland","Portugal","Serbia","Slovakia","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["35898703","35142815"],"seeAlso":["http://www.viablestudy.com"]},"adverseEventsSummary":{"seriousAny":{"events":237,"n":749},"commonTop":["Fatigue","Alopecia","Diarrhoea","Nausea","Oedema peripheral"]}}